In silico evaluation of potential drugs for the treatment of Colorectal Carcinoma

To evaluate possible new drugs for the treatment of Colorectal Carcinoma (CRC) using in silico tools was main objective this study. The method analysis used evaluation tumor markers and their interaction with selected drugs, through study its pharmacokinetic pharmacodynamic characteristics. A potential therapeutic target pointed out Cell Division Cycle 25 B (CDC25B), belonging to CDC25 phosphatase family. Overexpression phosphatases is often associated a wide variety cancers. In addition, CDC25B an oncogenic protein that induces neoplastic transformation. CRC, overexpressed activate CDC2/cyclin complex improve growth survival these tumors. Four were identified evaluation, α-amyrin being docking, because it had best characteristics according methodology used. ligand obtained energy value -7.6 G (Kcal/mol), while standard -10.0 (Kcal/mol). TThe results showed only structure cocrystallized presented favorable outcomes candidate further studies use CRC targeted therapy.